|
Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial). |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Roche; Seagen; Takeda |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Novartis; Roche; Sandoz |
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Novartis; Roche; Sandoz |
|
|
Honoraria - Celgene; Janssen-Cilag |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag |
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen-Cilag |
|
|
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Janssen |
Other Relationship - Amgen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Takeda |
Honoraria - Genmab; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Genmab; Janssen-Cilag; Takeda |
Research Funding - Genmab (Inst); Janssen-Cilag (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Sanofi |
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Mundipharma; Novartis; Sanofi |